Acalabrutinib Market, Global Outlook and Forecast 2023-2028

Report ID: 1134319 | Published Date: Jan 2025 | No. of Page: 66 | Base Year: 2024 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).
This report contains market size and forecasts of Acalabrutinib in Global, including the following market information:
Global Acalabrutinib Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Acalabrutinib market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Biopharmaceutical Grade Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Acalabrutinib include AstraZeneca Pharmaceuticals LP, Cephalon, Inc, Genentech, Inc and Cayman Chemical Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acalabrutinib companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acalabrutinib Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Acalabrutinib Market Segment Percentages, by Type, 2021 (%)
Biopharmaceutical Grade
Laboratory Grade
Global Acalabrutinib Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Acalabrutinib Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Acalabrutinib Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Acalabrutinib Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acalabrutinib revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Acalabrutinib revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca Pharmaceuticals LP
Cephalon, Inc
Genentech, Inc
Cayman Chemical Company

Frequently Asked Questions
Acalabrutinib Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Acalabrutinib Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Acalabrutinib Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports